PMC:7795856 / 3899-4273 JSONTXT

{"project":"LitCovid-PubTator","denotations":[{"id":"116","span":{"begin":129,"end":132},"obj":"Gene"},{"id":"117","span":{"begin":183,"end":189},"obj":"Gene"},{"id":"118","span":{"begin":262,"end":265},"obj":"Gene"},{"id":"119","span":{"begin":333,"end":339},"obj":"Gene"},{"id":"125","span":{"begin":97,"end":105},"obj":"Species"},{"id":"126","span":{"begin":312,"end":318},"obj":"Species"},{"id":"131","span":{"begin":169,"end":179},"obj":"Chemical"},{"id":"132","span":{"begin":221,"end":231},"obj":"Chemical"},{"id":"138","span":{"begin":88,"end":96},"obj":"Disease"},{"id":"139","span":{"begin":287,"end":306},"obj":"Disease"},{"id":"140","span":{"begin":348,"end":355},"obj":"Disease"}],"attributes":[{"id":"A116","pred":"tao:has_database_id","subj":"116","obj":"Gene:134864"},{"id":"A117","pred":"tao:has_database_id","subj":"117","obj":"Gene:1493"},{"id":"A118","pred":"tao:has_database_id","subj":"118","obj":"Gene:20539"},{"id":"A119","pred":"tao:has_database_id","subj":"119","obj":"Gene:12477"},{"id":"A125","pred":"tao:has_database_id","subj":"125","obj":"Tax:9606"},{"id":"A126","pred":"tao:has_database_id","subj":"126","obj":"Tax:10090"},{"id":"A131","pred":"tao:has_database_id","subj":"131","obj":"MESH:D000074324"},{"id":"A132","pred":"tao:has_database_id","subj":"132","obj":"MESH:D000074324"},{"id":"A138","pred":"tao:has_database_id","subj":"138","obj":"MESH:D008545"},{"id":"A139","pred":"tao:has_database_id","subj":"139","obj":"MESH:D007410"},{"id":"A140","pred":"tao:has_database_id","subj":"140","obj":"MESH:D003092"}],"namespaces":[{"prefix":"Tax","uri":"https://www.ncbi.nlm.nih.gov/taxonomy/"},{"prefix":"MESH","uri":"https://id.nlm.nih.gov/mesh/"},{"prefix":"Gene","uri":"https://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"CVCL","uri":"https://web.expasy.org/cellosaurus/CVCL_"}],"text":"ive study evaluating clinical phase II data reported an increase in overall survival of melanoma patients receiving sequentially Tα1 and the immune checkpoint inhibitor ipilimumab, a CTLA-4-blocking antibody, compared to ipilimumab therapy alone [16]. Moreover, Tα1 was shown to prevent intestinal toxicity in a murine model of anti-CTLA-4-induced colitis, hence contributin"}

{"project":"LitCovid-PD-HP","denotations":[{"id":"T10","span":{"begin":88,"end":96},"obj":"Phenotype"},{"id":"T11","span":{"begin":348,"end":355},"obj":"Phenotype"}],"attributes":[{"id":"A10","pred":"hp_id","subj":"T10","obj":"http://purl.obolibrary.org/obo/HP_0002861"},{"id":"A11","pred":"hp_id","subj":"T11","obj":"http://purl.obolibrary.org/obo/HP_0002583"}],"text":"ive study evaluating clinical phase II data reported an increase in overall survival of melanoma patients receiving sequentially Tα1 and the immune checkpoint inhibitor ipilimumab, a CTLA-4-blocking antibody, compared to ipilimumab therapy alone [16]. Moreover, Tα1 was shown to prevent intestinal toxicity in a murine model of anti-CTLA-4-induced colitis, hence contributin"}